300204.SZ
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 21.00
−5.32%Sep 18, 2026, 08:18 UTC
China's National Medical Products Administration accepted the clinical trial application (CXSL2601019) for a new indication of Bojianing (pomitease alfa for injection) by Jiangsu Beijiatai Biotechnology, a subsidiary of Staidson, for the treatment of major surgical bleeding.
Source:Aug 3, 2026, 07:51 UTC
Shutaishen announced that Bai Xuelian, general manager of its clinical research center, resigned for personal reasons and will no longer hold any position in the company.
Source:Aug 1, 2026, 01:53 UTC
Multiple fund companies participated in Shutaishen's private placement, subscribing shares with a six-month lockup period.
Source: